Search Results 1-10 of 17500 for anti-TNF drugs
Approved in 1998 for use in treating Crohn's disease and subsequently in 2005 for treating ulcerative colitis, anti-tumor necrosis factor (TNF) agents have ...
The purpose of this study is to compare the effectiveness of specific therapies to treat children with CD and UC/IBD-U refractory to anti-TNF therapy.
However, many CD and UC patients still ultimately require surgery despite the use of these medications. Side effects of the anti-TNF agents include increased ...
... medications such as the anti-Tumor Necrosis Factor (anti-TNF) agents infliximab, adalimumab, and certolizumab. However, many CD and UC patients still ...
In one of the balancing acts of medicine, the anti-inflammatory action of the drug also increases the risk for other conditions, in this case, a rare form of ...
The purpose of this study is to evaluate infliximab drug levels and anti-infliximab antibody levels in HiSCR50/IHS4 responders versus non-responders at week 18.
Psoriatic arthritis usually occurs with a skin condition called psoriasis. Adalimumab may be used alone or in combination with medicines (eg, methotrexate or ...
Anti-TNF agents: TNF blockers. This type of biologic medicine helps calm ulcerative colitis by blocking the actions of an immune system protein called tumor ...
The purpose of this study is to determine whether adding low dose methotrexate to anti -TNF therapy is more effective than treatment with anti-TNF therapy alone ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift doubles in impact to help more patients.